Form 4: Director Ortenzio Receives Concentra Stock Grant

Concentra Group Holdings Parent, Inc. Director Robert A. Ortenzio was granted 7,748 shares of common stock, vesting in November 2026.

Summary

• Robert A. Ortenzio, a Director of Concentra Group Holdings Parent, Inc. (CON), acquired 7,748 shares of common stock.
• The transaction occurred on November 4, 2025, and was a grant of restricted stock.
• These shares were acquired at a price of $0 per share.
• The restricted stock is subject to certain exceptions and will vest in full on November 4, 2026, the first anniversary of the grant date.
• Following this transaction, Mr. Ortenzio directly beneficially owns 5,533,794 shares of common stock.
• He also indirectly beneficially owns 1,023,455 shares via The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio, 1,032,115 shares via the Robert A. Ortenzio Descendants Trust, and 226,286 shares each via the Robert A. Ortenzio 2014 Trust for Bryan A. Ortenzio, Kevin M. Ortenzio, and Madeline G. Ortenzio, totaling 2,734,428 indirect shares.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is generally a positive sign of alignment between management/board and shareholders, but it does not contain significant new operational or financial news to warrant a higher score. It's a standard, expected event.

Positives

• Director Robert A. Ortenzio received a grant of 7,748 shares of common stock, aligning his interests with shareholders.
• The grant price of $0 indicates it is likely part of an equity compensation plan, a common practice to incentivize directors.

Risks

• The restricted stock grant is subject to certain exceptions before vesting, meaning the shares are not immediately fully owned and could be forfeited under specific conditions.

Future Outlook

The 7,748 shares of restricted stock granted to Director Robert A. Ortenzio are scheduled to vest in full on November 4, 2026, subject to certain exceptions.

Industry Context

Equity grants to directors are a standard practice across various industries to align leadership interests with long-term shareholder value. This transaction reflects a routine compensation component for a director in the healthcare services sector, where Concentra operates.

Comparison to Industry Standards

• The grant of restricted stock to a director at a $0 price is a common form of equity compensation, aligning with typical industry practices for incentivizing and retaining board members.
• Many publicly traded companies, including peers in the healthcare services industry, utilize similar equity-based compensation structures for their non-employee directors. For example, companies like HCA Healthcare or Tenet Healthcare often include restricted stock units (RSUs) or stock options as part of their director compensation packages, with vesting schedules designed to promote long-term commitment.
• The size of the grant (7,748 shares) would need to be benchmarked against Concentra's market capitalization and the typical compensation for directors at similarly sized companies to assess its relative value, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value.

Next Steps

• The granted restricted stock will vest on November 4, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock to a director as part of their compensation. While it indicates continued alignment of interests between the director and shareholders, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in an investor's current position. It's a standard disclosure for an expected event.

Keywords

Concentra Group Holdings Parent Inc, CON, Robert A. Ortenzio, Form 4, Insider Transaction, Stock Grant, Restricted Stock, Director Compensation, Equity Compensation